Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

Summary

The primary aim is to collect data to determine the correct effect size on the primary outcome to aid in the design of a larger study: The primary outcome is to determine if lipoic acid and omega-3 fatty acids can improve cognitive function in people with multiple sclerosis that have cognitive dysfunction.

Timeline

Start

2014-06

Primary completion

2016-05

Completion

2016-05

Outcome

Missed primary endpoint

registry Lipoic Acid and Omega-3 Fatty Acids vs Placebo; p = 0.05; Mean Difference (Final Values) 1.14 (95% CI -2.03 to 4.32); t-test, 2 sided NCT02133664 ↗

Drugs

Indications